---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001711"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:38:39.148189+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Calidi refiles FY2023 financials to reflect 1-for-10 reverse stock split

## Summary
- 1-for-10 reverse stock split effective July 15, 2024, retroactively applied to FY2023 statements.
- Exhibits incorporated by reference from December 12, 2024 S-1; no change to non-split information.
- All other 2023 Annual Report information remains unchanged.

## SEC filing metadata
- accession: 0001493152-25-001711
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225001711/0001493152-25-001711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225001711/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001711
- JSON: https://secwatch.observer/filing/0001493152-25-001711.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.